AFAR is a medical device company headquartered in Singapore responsible for developing a series of revolutionary wound care and OTC products. The day to day operations of the company focus on innovative R&D and aggressive patenting of commercially viable products. The business model employs both own brand sales and licensing of our technology to larger industry participants with appropriate distribution, sales, and marketing. The Team works to make it as easy as possible to license the technology by partnering with first class manufacturers, undertaking clinical trials and completing regulatory approvals. To date, AFAR products have received HSA (Singapore), CE (Europe), ANVISA (Brazil) and TGA (Australia) regulatory approvals and been awarded patents from the UPTO with patents filed on all other products.